Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Rishi Wadhera, MD | Image Credit: Beth Israel Deaconess

Journal of the American College of Cardiology

 risk factors and the 5 conditions that collectively account for most CVD deaths and disability in the US.

The report aims to analyze disease burden, quality of care, and mortality trends for each of the risk factors – 

, and cigarette smoking – and conditions – 

. The investigators aimed to determine where progress has been made in recent years and what must still be done to optimize care and provide treatment to all patients equally.

’s most important responsibilities: to help our community see clearly where we stand,” Rishi Wadhera, MD, cardiologist at Beth Israel Deaconess Medical Center, associate professor of medicine at Harvard Medical School, and lead author of the report, said in a statement. “Progress in cardiovascular health has always depended on data—on our willingness to reflect the evidence clearly, to face uncomfortable truths, and to use evidence to guide action.”

Each risk factor is analyzed via nationally representative surveys, administrative claims, clinical registries, and vital statistics. Wadhera and colleagues found persistent disparities across all risk factors and conditions, primarily by race, geography, and socioeconomic status. The report also highlights areas of incomplete data.

Among the findings in the document, the most critical are as follows:

The prevalence of diabetes and mortality therefrom is increasing among young adults and low-income populations

Obesity can now be considered an epidemic, as >40% of US adults are now affected

Hypertension affects 1 in 2 US adults, with no significant change since 2009

Most high-risk adults fail to reach their LDL-C targets, while statin use remains limited

AMI hospitalizations declined from 2004 to 2010, but young adult AMI hospitalizations have risen in recent years

PAD affects roughly 1 in 14 adults, and nearly half of those undergoing peripheral vascular interventions are not given full guideline-directed medical therapy at discharge

CHD impacts >20.5 million US adults; these rates have steadily increased since 2019

HF affects roughly 6.7 million adults. Although mortality rates decreased steadily from 1999 to 2011, the COVID-19 pandemic brought about a sharp increase

Stroke accounts for roughly 1 in 20 deaths in 2023.

Because the document focuses primarily on updating clinicians on recent data, it provides few practice-changing guidelines. Instead, it provides perspective, aiming to encourage both clinicians and policymakers to approach the issue of CVD from alternative angles to minimize disparities and optimize treatment.

“If we want a healthier future, we must understand how far we have come, how far we have yet to go, and what stands in our way,” wrote Harlan Krumholz, MD, editor-in-chief of 

’s collective awareness, we aim to help the cardiovascular community, including clinicians, researchers, policymakers, and the public, see the landscape clearly and chart a more effective path forward.”

 also announced plans to release the document annually, at the beginning of every year. The investigators plan to expand it to include additional conditions and populations in the future.

American College of Cardiology. JACC Issues Inaugural Report on State of US Cardiovascular Health. 

 January 12, 2026. Accessed January 12, 2026. 

https://www.eurekalert.org/news-releases/1112013

Wadhera, R, Dhruva, S, Bikdeli, B. et al. Cardiovascular Statistics in the United States, 2026: JACC Stats. 

https://doi.org/10.1016/j.jacc.2025.12.027

Articles

The inaugural JACC Cardiovascular Statistics report, published in January 2026, evaluates five major cardiovascular disease risk factors and conditions contributing to CVD mortality and disability in the US. It highlights persistent disparities in CVD risk factors and conditions, particularly by race, geography, and socioeconomic status. The report underscores the increasing prevalence of diabetes, obesity, and hypertension, and the rise in young adult AMI hospitalizations. It aims to provide perspective rather than practice-changing guidelines, encouraging clinicians and policymakers to address disparities and optimize treatment strategies.

The report details the disease burden, mortality, and quality of care trends for 5 major risk factors and the 5 leading causes of CVD death.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

JACC Inaugural Cardiovascular Studies Report Highlights Progress and Potential for Growth

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!

Interested in a more traditional, text rundown? 

Top 5 Healthcare Headlines for January 3-10, 2025:

Here are one-sentence, clinician-focused summaries with titles restated and no statistics included:

FDA Approves Caplacizumab-yhdp (Cablivi) as First Pediatric aTTP Therapy

The FDA approved caplacizumab for adolescents with aTTP, making it the first therapy specifically indicated for pediatric patients with this condition.

Pemvidutide Gets Breakthrough Therapy Designation for MASH

The FDA granted Breakthrough Therapy Designation to pemvidutide for MASH, supporting its accelerated development based on promising mid-stage clinical data and alignment on a registrational phase 3 program.

FDA Grants Priority Review Of Biologics License Application For Atacicept In IgA Nephropathy

The FDA granted Priority Review to the BLA for atacicept, advancing a potential new biologic therapy for adults with IgA nephropathy.

FDA Approves 2-Gram Presentation of Fibryga for Acquired Fibrinogen Deficiency

The FDA approved a higher-dose presentation of Fibryga, expanding dosing flexibility for fibrinogen replacement in patients with acquired fibrinogen deficiency.

FDA Accepts for Priority Review sBLA for Teplizumab for Children With Stage 2 T1D

The FDA accepted a Priority Review sBLA for teplizumab to expand its use to younger children in order to delay progression to clinical type 1 diabetes.

The recent healthcare updates include significant FDA approvals and designations. Caplacizumab-yhdp has been approved as the first pediatric therapy for aTTP, while pemvidutide received Breakthrough Therapy Designation for MASH, indicating promising clinical data. Atacicept's Biologics License Application for IgA nephropathy has been granted Priority Review, potentially offering a new treatment option. Additionally, a 2-gram presentation of Fibryga has been approved for acquired fibrinogen deficiency, enhancing dosing flexibility. Lastly, teplizumab's sBLA for children with Stage 2 T1D has been accepted for Priority Review, aiming to delay disease progression.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Type 1 Diabetes

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

HCPLive 5 Stories in Under 5: Week of 01/04

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Dupilumab therapy provides clinically meaningful improvements in 

 compared to other options, new data suggest, supporting its use as the preferred first-line medication.

These new findings resulted from a recent analysis authored by such investigators as András Bánvölgyi, MD, PhD, of Semmelweis University in Budapest, Hungary. Bánvölgyi and colleagues noted the debilitating itch-scratch cycle of prurigo nodularis, describing the condition as a chronic, intensely itchy skin disease characterized by hyperkeratotic nodules.

Additionally, they noted some of the biggest therapeutic challenges of prurigo nodularis result from the wide array of treatment modalities, from topical corticosteroids and calcineurin inhibitors to phototherapy.

“Here, we aimed to conduct a systematic review and meta-analysis to evaluate the efficacy and safety of available therapies for PN, including both conventional and biologic therapies,” Bánvölgyi and coauthors highlighted.

Bánvölgyi et al carried out a comprehensive literature search in November 2023, implementing the Embase, PubMed, and CENTRAL databases for their analysis. They had 2 independent reviewers screen existing citations at both the title and abstract stage and during full-text review to determine their eligibility for inclusion. The team considered these studies if they enrolled individuals diagnosed with prurigo nodularis who had been on therapies specifically intended to manage this disease.

The investigators did not place limitations on geographic area or coexisting medical conditions, although studies limited solely to pediatric patients were not evaluated. Criteria for inclusion were structured according to the population–intervention–control–outcome framework, with adults with prurigo nodularis as the population, biologic drugs as the intervention, conventional therapies, placebo, or no therapies as comparators, and outcomes including itch severity improvement, reduction in any nodular lesions, shifts in quality-of-life, and findings related to safety.

The investigative team also looked into any observed safety findings, evaluating such data by the frequency of adverse event (AE) occurrences. They performed random-effects meta-analyses when data quantity and quality allowed for such assessments. From a total of 4914 records identified and screened, there were 128 studies which were shown to have met inclusion criteria for qualitative synthesis. Bánvölgyi and colleagues found 25 provided sufficient information to be incorporated into their meta-analyses.

In looking at studies on dupilumab’s use in prurigo nodularis, the drug’s use was linked to substantial reductions in severity of pruritus, with a mean difference of −5.76 (95% CI, −6.86 to −4.67). The investigators also noted significant improvements in study participants’ quality of life, as indicated by a mean difference of −11.84 (95% CI, −22.76 to −0.92). AEs were seen in 13% of individuals being treated with dupilumab (95% CI, 0.02–0.52). This, the team wrote, suggested an overall favorable safety profile.

Among the non-biologic options highlighted in their analysis, phototherapy produced complete responses in 23% of participants evaluated (95% CI, 9%–48%). Phototherapy also led to partial responses in 60% (95% CI, 39%–78%), and a complete non-response in 7% (95% CI, 1%–40%). Treatment via thalidomide resulted in complete response rates of 15% of participants (95% CI, 1%–71%). Bánvölgyi and coauthors also noted partial responses after using thalidomide in 49% (95% CI, 23%–75%) and a lack of response in 12% of cases (95% CI, 6%–23%).

Overall, the cumulative data in this analysis pointed to dupilumab as a medication leading to consistent and clinically meaningful benefits for those with prurigo nodularis. Bánvölgyi and colleagues also highlighted dupilumab’s comparatively reassuring safety profile. These data collectively support the drug’s role as a preferred first-line therapeutic. In contrast, phototherapy and thalidomide may be considered for select cases, as their use was associated with decreased rates of complete disease clearance and greater safety-related limitations.

From a research perspective, the investigative team’s findings highlight the necessity of further randomized clinical trials to better determine the efficacy of emerging therapies, especially newer biologics and Janus kinase (JAK) inhibitors. Bánvölgyi et al noted the value of direct comparative studies between biologics and JAK inhibitors for the purposes of examining any differences in efficacy and safety.

Further investigation into patterns of relapse, long-term medication durability, and standardized outcome measures was also described by the team as potentially helpful to help reduce heterogeneity across research and strengthen the base of evidence for management options.

“Dupilumab provides consistent, clinically meaningful improvements in PN with a favorable safety profile, supporting its use as the preferred first-line treatment option when available,” the investigators concluded.

 “Phototherapy and thalidomide remain alternatives for selected patients, but achieve complete clearance only in a few cases and have harbored significant safety concerns.”

Lancz A, Meznerics FA, Bánvölgyi A, et al. Efficacy and Safety of Conventional and Biologic Therapies in Prurigo Nodularis: A Systematic Review and Meta-Analysis. Int J Dermatol. 2026 Jan 6. 

Müller S, Zeidler C, Ständer S. Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments. Am J Clin Dermatol. 2024 Jan;25(1):15-33. doi: 10.1007/s40257-023-00818-z. Epub 2023 Sep 17. PMID: 37717255; PMCID: PMC10796623.

Dupilumab therapy demonstrates significant efficacy and safety in managing prurigo nodularis, surpassing other treatment options. A systematic review and meta-analysis by Bánvölgyi et al. evaluated various therapies, highlighting dupilumab's ability to reduce pruritus severity and improve quality of life. The study also noted the drug's favorable safety profile, with adverse events occurring in 13% of patients. While phototherapy and thalidomide are alternatives, they show limited complete response rates and safety concerns. Further research is needed to explore emerging therapies and improve treatment strategies.

This systematic search of databases was conducted to identify research evaluating drugs used for prurigo nodularis (PN).

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Dupilumab Most Effective Among Standard Drugs, Biologics in Prurigo Nodularis

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

An artificial intelligence (AI)–assisted model may support earlier detection of

, according to findings from a new study.

The findings are derived from the ZEbra Bodies Recognition by Artificial Intelligence (ZEBRA) pipeline, which investigators describe as a potential new histological measure of podocyte involvement in FN.

“AI applications have been explored for tasks such as glomerular classification, segmentation, and quantification of histological features, aiming to augment traditional pathology workflow,” wrote investigator Vincenzo L’Imperio, MD, from the University of Milano-Bicocca. “In the context of FN, the diagnostic challenge is represented by the insidious clinical presentation that can be totally unspecific.”

FD is a rare lysosomal storage disorder caused by intracellular globotriaosylceramide (Gb3) accumulation, which can lead to progressive organ damage. Renal involvement, FN, is a major contributor to morbidity and mortality and may present with proteinuria, declining kidney function, and, in advanced stages, end-stage renal disease.

Despite these risks, FN is often difficult to diagnose, particularly in its early stages. Clinical presentation may be nonspecific or clinically silent, especially in patients with late-onset or atypical variants and in female patients, in whom X-chromosome inactivation can attenuate disease expression. As a result, kidney involvement may go unrecognized until irreversible damage has occurred.

Renal biopsy remains a cornerstone of early FN detection, allowing identification of Gb3-related podocyte changes on light and electron microscopy before overt systemic manifestations develop. However, diagnosis relies heavily on nephropathologist expertise, as hallmark features such as podocyte cytoplasmic vacuolization can be subtle, focal, or unevenly distributed, particularly in atypical or female cases. Against this backdrop, AI-assisted digital pathology has emerged as a potential adjunct to renal biopsy interpretation.

To assess whether AI could assist in identifying early FN-related changes, L’Imperio and colleagues conducted a multicenter analysis of formalin-fixed, paraffin-embedded renal biopsies collected over a 15-year period from patients with genetically confirmed FD. Investigators trained multiple AI-based classification and segmentation models to detect foamy podocytes at the glomerular level.

Building on this framework, the team developed a custom inference pipeline, ZEBRA, designed to streamline glomerular annotation and quantify podocyte involvement in a reproducible manner. The ZEBRA algorithm integrates a glomerular-level classification component with a segmentation module that delineates affected podocytes at the microscopic level. 

Using the ZEBRA model, investigators calculated the proportion of glomerular area occupied by foamy podocytes (fpA) relative to total glomerular area (tgA), generating the ZEBRA score (ZS = fpA/tgA, expressed as a percentage).

The study included 77 participants, divided into FN cases (n = 37) and controls (n = 40). All patients underwent kidney biopsy based on standard nephrological indications, such as persistent proteinuria (>0.5–1 g/day), hematuria, unexplained decline in kidney function, or other laboratory or clinical findings, regardless of whether FD was suspected at the time of biopsy.

In total, investigators analyzed 1,075 glomeruli from FN cases and 689 from controls. Compared with controls, FN cases had higher estimated glomerular filtration rate (mean 98 vs 69 ml/min/1.73 m²; 

 <.001), lower proteinuria (median 0.2 vs 1.28 g/day; 

 <.001), and milder interstitial fibrosis and tubular atrophy (

 = .01), underscoring the early-stage nature of kidney involvement in many FN cases.

Upon receiver operating characteristic analysis, investigators observed strong diagnostic performance for the ZEBRA score, with an area under the curve of 0.93. A preliminary cutoff of 0.19 (mean ZS per case) yielded a sensitivity of 0.91 and a specificity of 0.81. The ZEBRA score also correlated with the manual podocyte vacuolization score in both hematoxylin and eosin–stained (rs = 0.66) and periodic acid–Schiff–stained slides (rs = 0.71), although case-level discrepancies were noted.

“This study introduces and validates a novel digital pathology pipeline for FN, culminating in the ZEBRA score, a new histological measure of podocyte involvement,” investigators concluded. “The AI system is designed as a high-sensitivity screening tool, providing comprehensive image analysis that can alert human operators to potential oversights and help prevent missed diagnoses.”

Investigators emphasized further studies are needed to evaluate the prognostic significance of the ZEBRA score and to determine its potential role in informing clinical decision-making in FD.

Cazzaniga G, Carbone M, Barretta R, et al. Zebra bodies recognition by artificial intelligence (ZEBRA): a computational tool for Fabry nephropathy. 

. Published online January 12, 2026. doi:

https://doi.org/10.1038/s41598-026-35466-w

Del Pino M, Andrés A, Bernabéu AÁ, et al. Fabry Nephropathy: An Evidence-Based Narrative Review. 

In a multicenter analysis, ZEBRA, an AI-assisted pathology tool, showed high sensitivity and specificity for detecting Fabry nephropathy in renal biopsies.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

RDR Alert®

The Rare Disease Report page is a resource for medical news and expert insights on rare diseases. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for sickle cell disease, multiple myeloma, and more.

AI-Based ZEBRA Model May Improve Detection of Fabry Nephropathy on Kidney Biopsy

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Tvardi Therapeutics reported additional phase 2 data from its REVERT IPF trial on January 8, 2026, showing that patients with idiopathic 

 (IFP) treated with the STAT3 inhibitor TTI-101 experienced greater reductions in lung fibrosis at 12 weeks compared with placebo.

“Our subsequent analyses of the REVERT IPF clinical trial data set revealed deeper insights into the impact of TTI-101 on the inhibition of STAT3 in fibrosis and inflammation,” said Tvardi Chief Executive Officer Imran Alibhai, PhD, in a statement.

 “Notably, treatment with TTI-101 was associated with improvement in blinded fibrosis scores vs placebo and reductions in IL-6 levels consistent with STAT3 pathway inhibition. Further interrogation into FVC after 12 weeks of TTI-101 was encouraging despite the placebo-treated patients’ FVC decline being lower than expected compared to historical controls.”

This update follows the October 13, 2025, announcement of preliminary results, in which the company reported that the study did not meet its primary objectives.

 In the initial analysis, 88 patients were randomized to TTI-101 400mg per day (n=30), 800mg per day (n=29) or placebo (n=29). The study was not powered to assess exploratory endpoints, with only 8 patients on 400 mg, 13 on 800 mg, and 24 on placebo who had efficacy data at 12 weeks.

The preliminary analysis of exploratory efficacy showed statistically significant differences between placebo and treatment arms.

 The study found 39% on 400 mg, 44% on 88 mg, and 41% on placebo demonstrated FVC improvement.

“The limited data set, high variability within treatment arms, and unexpected performance of the placebo arm make it difficult to provide more definitive conclusions at this time,” Alibhai said in an October 2025 statement.

Due to the lack of significant data, investigators conducted a secondary analysis of REVERT IPF, a phase 2, randomized, double-blind, placebo-controlled trial assessing TT-1010 alone or in addition to nintedanib (OFEV) in patients with IPF.

 The team sought to assess the safety, pharmacokinetics, and exploratory outcomes of TT-101 related to lung function.

The study only included patients exposed to TT-101 for 12 weeks; the trial excluded patients with < 60% of the expected dosing (n = 1) no measurable TT-101 in the blood (n = 2), and no reported adverse events (n = 2). One participant was excluded after initially showing improvement in pulmonary function on TTI-101 but later experiencing a decline due to acute bronchitis deemed unrelated to the study drug.

REVERT IPF included 40 patients, with 16 randomized to TTI-1010 and 24 randomized to placebo. The study observed a greater fibrosis decline from baseline to week 12 on the high-resolution CT lung fibrosis score in patients treated with TTI-101 compared to placebo (-9.4% vs -2.4%). Patients on TTI-101 vs placebo also experienced a greater IL-6 decline, especially among patients in the TT1-101 arm who had greater baseline IL-6.

Furthermore, 63% of patients treated with TTI-1010 demonstrated an increase in forced vital capacity (FVC) at 12 weeks, compared with 46% on placebo. The mean FVC change in patients treated with TTI-101 was -15 mL, which was less of a decline compared to patients on placebo (-22 mL).

“With these data in-hand, we eagerly await results from the ongoing healthy volunteer study of our next-generation STAT3 inhibitor, TTI-109,” Alibhai continued. “TTI-109 is designed to enhance TTI-101’s ability to target STAT3 as a more efficient delivery vehicle with the potential to improve tolerability. If successful, we will move quickly to identify next steps for this promising, potentially disease modifying therapy across a range of fibrosis-driven diseases where STAT3 activation is implicated.”

Tvardi Therapeutics Announces Further Phase 2 REVERT IPF Data, Expanding Clinical Insights. GlobeNewsWire. Published on January 8, 2026. Accessed January 12, 2026. 

https://www.globenewswire.com/news-release/2026/01/08/3215337/0/en/Tvardi-Therapeutics-Announces-Further-Phase-2-REVERT-IPF-Data-Expanding-Clinical-Insights.html

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis. Tvardi Therapeutics. Published on October 13, 2025. Accessed January 12, 2026. 

https://ir.tvarditherapeutics.com/news-releases/news-release-details/tvardi-therapeutics-provides-update-preliminary-data-phase-2

Tvardi Therapeutics' phase 2 REVERT IPF trial revealed that the STAT3 inhibitor TTI-101 significantly reduced lung fibrosis in idiopathic pulmonary fibrosis patients compared to placebo over 12 weeks. Despite initial results not meeting primary objectives, secondary analyses showed promising outcomes, including improved fibrosis scores and reduced IL-6 levels. The trial faced challenges due to high variability and unexpected placebo performance. TTI-101 demonstrated a greater forced vital capacity increase than placebo. Tvardi is now focusing on TTI-109, a next-generation STAT3 inhibitor, aiming for enhanced delivery and tolerability.

Patients with idiopathic pulmonary fibrosis treated with the STAT3 inhibitor TTI-101 had greater reductions in lung fibrosis scores and IL-6 levels than placebo at 12 weeks.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Pulmonary Fibrosis

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101

David Armstrong, MD, PhD, is a distinguished professor of surgery and neurological surgery at Keck School of Medicine of USC.

Videos

Armstrong discusses the positive time-to-healing data from the phase 2 LEGenD-1 study, investigating anatomically targeted delivery of AMG0001.

Gene Therapy Accelerates Ulcer Healing in Limb-Threatening Ischemia, With David Armstrong, DPM, PhD

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Tirzepatide Boosts Izekizumab Efficacy for PsA and Obesity Disease Control

Bristol Myers Squibb has reported positive results from the ongoing SCOUT-HCM trial, demonstrating mavacamten’s efficacy in reducing Valsalva LVOT.

Cardiomyopathy

SCOUT-HCM: Mavacamten Achieves Positive Results in Adolescents with Obstructive HCM

A retrospective analysis links low pretransplant exercise tolerance with reduced skeletal muscle recovery and persistent sarcopenia risk after living donor kidney transplantation in CKD.

Chronic Kidney Disease

Low Exercise Tolerance Before Kidney Transplant Signals Poor Muscle Recovery

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The NDA is supported by data from the phase 3 TRIUMpH clinical program and seeks approval for heartburn in NERD, healing of erosive esophagitis, and maintenance of healing.

Gastroesophageal Reflux Disease (GERD)

The HCPLive gastroesophageal reflux disease page is a comprehensive resource for clinical news and insights on GERD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for reflux disease, and more.

Tegoprazan NDA Seeks FDA Approval for 3 GERD Indications

In this retrospective single-center analysis, adult patients with moderate-to-severe atopic dermatitis treated with dupilumab were evaluated for super responder status.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Predictors Identified for Super-Responder Status to Dupilumab in Atopic Dermatitis

The panel focuses on how quality of life considerations shape ATTR-CM management. Beyond survival and hospitalization outcomes, many patients most value being able to remain mobile and independent—continuing activities such as walking, gardening, or caring for grandchildren. Even subjective concerns like weight loss or appearing “frail” can meaningfully affect how patients feel about their health. Managing symptoms of congestion and reducing the need for frequent diuretic adjustments also plays an important role in daily well-being.
The discussion then highlights recent data from HFSA showing that vutrisiran was associated with fewer gastrointestinal symptoms, such as diarrhea and constipation. The panel found this particularly interesting in wild-type ATTR-CM, where GI involvement is not always recognized. Improvements in GI comfort can support better nutrition, energy, and overall day-to-day function. Across the conversation, the experts emphasize that maintaining function and stability over time is often the clinical outcome patients value most.


Video Series

Quality of Life and GI Tolerability in ATTR-CM Management

In this episode, the panelists review long-term efficacy data for bimekizumab presented at EADV 2025, focusing on sustained remission and disease control in psoriasis. The experts highlight that approximately 49% of patients maintained complete skin clearance (PASI 100) from month 4 through year 4, with about 72% sustaining complete or near-complete clearance over the same period. They interpret these findings as strong evidence of durability and depth of response, underscoring bimekizumab’s ability to maintain remission over years rather than months. The discussion also includes nail outcomes, with nearly 80% of patients maintaining NAPSI 0, indicating resolution of nail involvement—an important factor given its association with psoriatic arthritis risk. The panelists emphasize that by achieving and maintaining high levels of clearance in both skin and nails, bimekizumab may help interrupt the inflammatory progression that leads to PsA, reinforcing its role in comprehensive disease control.

Evaluating Long-Term Remission and Disease Control with Bimekizumab in Psoriasis

Explore diagnostic challenges in severe pediatric skin disease, common management pitfalls, and when to escalate to systemic or biologic therapy.

Severe Pediatric Dermatoses: Diagnostic Pitfalls and Early Systemic Therapy

The panel discusses decision-making around monotherapy versus dual therapy in ATTR-CM. They explain that while there is not definitive, statistically significant evidence supporting routine dual therapy for all patients, there is also no evidence of harm when stabilizers and silencers are used together. Because the two therapeutic classes work through different mechanisms, dual therapy is considered reasonable in selected patients, particularly when the goal is to slow progression as much as possible.
The panel emphasizes that treatment decisions should be individualized, guided by disease stage, symptom burden, neurologic involvement, patient priorities, and access considerations. They stress that ATTR-CM is not a uniform disease, and two patients with the same diagnosis may have completely different clinical needs. Ultimately, the group agrees that the only clearly inappropriate choice is providing no disease-modifying therapy at all.


Latest News

JACC Inaugural Cardiovascular Studies Report Highlights Progress and Potential for Growth

HCPLive 5 Stories in Under 5: Week of 01/04

Dupilumab Most Effective Among Standard Drugs, Biologics in Prurigo Nodularis

AI-Based ZEBRA Model May Improve Detection of Fabry Nephropathy on Kidney Biopsy

Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101